Form 4: Astria Therapeutics Director Fred Callori Acquires Stock Options

Fred Callori, a director of Astria Therapeutics, acquired 14,100 stock options on June 5, 2024.

Summary

• On June 5, 2024, Fred Callori, a director of Astria Therapeutics, acquired 14,100 stock options.
• The exercise price of these options is $9.18.
• The options vest in full on June 5, 2025, contingent upon Callori's continued service as a director.
• Following the transaction, Callori directly owns 14,100 derivative securities.

Sentiment

Score: 6

Explanation: The document simply reports a transaction. It's neutral in tone, reflecting a standard practice of granting stock options to a director.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

This is a standard practice for compensating and incentivizing board members in publicly traded companies.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with shareholders.
• The vesting schedule of one year is fairly standard.
• The number of options granted is dependent on the size and stage of the company, and the director's role and responsibilities.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders.

Key Dates